MDK-701 is under clinical development by Medikine and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MDK-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MDK-701 is under development for the treatment of solid tumors. The drug candidate is a fusion protein of synthetic peptide (MDK1319) and IgG Fc-domain. It acts by targeting interleukin 7 receptor (IL-7Ragc). It is administered through parenteral route.
For a complete picture of MDK-701’s drug-specific PTSR and LoA scores, buy the report here.